Reply to M.S. Aapro

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages

  Stopeck, Alison T ^a   Lipton, Allan ^b   Body, Jean Jacques ^c   Steger, Guenther G ^d   Tonkin, Katia ^e   De Boer, Richard H ^f   Fujiwara, Yasuhiro ^g   Yardley, Denise A ^h   Viniegra, María ⁱ   Fan, Michelle ^j   Jiang, Qi ^j   Dansey, Roger ^j   Jun, Susie ^j   Braun, Ada ^j  

^a UNIVERSITY OF ARIZONA   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e CROSS CANCER INSTITUTE   (Canada)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ Servicio de Oncologia   (Argentina)

^j AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; BONE METASTASIS; BONE NECROSIS; CANCER PATIENT; CATABOLISM; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RETICULOENDOTHELIAL SYSTEM; SURVIVAL;

EID: 79955806308     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1511     Document Type: Letter

References (22)

1. Aapro MS: Denosumab for bone metastases from breast cancer: A new therapy option? J Clin Oncol 29:e419-e420, 2011
2. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zole-dronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
3. US Department of Health and Human Services, Food and Drug Administration: Guidance for Industry Non-Inferiority Clinical Trials (DRAFT). 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM202140.pdf
4. European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products (CPMP): Points to Consider on Switching Between Superiority and Non-Inferiority. 2000. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2014556/
5. Zometa (zoledronic acid) injection, concentrate for intravenous infusion [prescribing information]. East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2009
6. Ibrahim A, Scher N, Williams G, et al: Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9:2394-2399, 2003 (Pubitemid 36842077)
7. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001 (Pubitemid 33759002)
8. Cimino MA, Rotstein C, Slaughter RL, et al: Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 83:1091-1097, 1987 (Pubitemid 18098883)
9. Launay-Vacher V, Gligorov J, Le Tourneau C, et al: Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124:745-753, 2010
10. Oh WK, Proctor K, Nakabayashi M, et al: The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 109:1090-1096, 2007 (Pubitemid 46435387)
11. Ries F, Klastersky J: Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368-379, 1986 (Pubitemid 17235084)
12. Aredia (pamidronate disodium) injection, for intravenous infusion [prescribing information]. East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2008
13. Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003 (Pubitemid 46606297)
14. Kennel KA, Drake MT: Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc 84:632-637; quiz 638, 2009
15. XGEVA (denosumab) injection, for subcutaneous use, [prescribing information]. Thousand Oaks, CA, Amgen Inc, 2010
16. Cardoso F, Senkus-Konefka E, Fallowfield L, et al: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v15-9 (suppl 5)
17. National Comprehensive Cancer Network: NCCN Guidelines, Version 2.2, Invasive Breast Cancer. 2010. http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp#site
18. Fizazi K, Lipton A, Mariette X, et al: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564-1571, 2009
19. Coleman R, Thorpe H, Cameron D, et al: Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE Trial (BIG 01/04), 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010
20. Amgen: XGEVA (denosumab) significantly improved bone metastasis-free survival in men with prostate cancer (press release). Thousand Oaks, CA, Amgen Inc, 2010
21. Gonzalez-Suarez E, Jacob AP, Jones J, et al: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107, 2010
22. Schramek D, Leibbrandt A, Sigl V, et al: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98-102, 2010